Anchiano Therapeutics Ltd.Anchiano Therapeutics Ltd. • January 7th, 2019 • Pharmaceutical preparations
This letter confirms our agreement and undertaking that subject to and following the initial public offering of American Depositary Receipts representing ordinary shares of Anchiano Therapeutics Ltd. (the “Company”) on the Nasdaq Global Market, Clal Biotechnology Industries Ltd. (the “Shareholder”) shall be entitled to the information rights set forth in this letter agreement (this “Agreement”), subject to the terms set forth herein.
